Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 1

Conditions

Stomach Neoplasms 6Uterine Cervical Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Gastric or Gastroesophageal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × bemarituzumab × Clear all
NCT05052801 2026-05-27

FORTITUDE-101

Amgen

Phase 3 Completed
547 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

Amgen

Phase 3 Active not recruiting
515 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Amgen

Phase 1/2 Active not recruiting
72 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Five Prime Therapeutics, Inc.

Phase 1 Completed
79 enrolled 21 charts
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 1 Completed
12 enrolled 17 charts
Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT03694522 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 2 Completed
155 enrolled 19 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡